We briefly analyzed the research design and results through summarizing the latest hot spots relevant to targeted therapy in combination with immunotherapy (Abbreviated as “combination therapy” ) for hepatocellular carcinoma (HCC), aiming to provide references for clinical decision-making and future research directions. It was found that the clinical study results related to combination therapy for HCC were different by summarizing the study design and results of combination therapy for HCC in recent years, which might be closely related to the study design, drug selection, research objects selection, protocol implementation, and other factors. It is suggested that a variety of factors such as disease background should be considered when combination therapy for HCC is conducted in order to obtain a more comprehensive and objective understanding.
